Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation Katharina MahalBernhard BiersackThomas Mueller PRECLINICAL STUDIES 14 February 2015 Pages: 541 - 554
Convection-enhancement delivery of platinum-based drugs and LipoplatinTM to optimize the concomitant effect with radiotherapy in F98 glioma rat model Minghan ShiDavid FortinBenoit Paquette PRECLINICAL STUDIES 18 March 2015 Pages: 555 - 563
Inhibition of human vascular endothelial cell migration and capillary-like tube formation by the microtubule-stabilizing agent peloruside A Ariane ChanA. Jonathan SinghJohn H. Miller PRECLINICAL STUDIES 31 March 2015 Pages: 564 - 574
Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and androgen receptor; in silico and in vitro Pushpendra SinghFelix Bast PRECLINICAL STUDIES 19 April 2015 Pages: 575 - 593
Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors Sarah A. HolsteinJames C. BigelowRaymond J. Hohl PHASE I STUDIES 21 February 2015 Pages: 594 - 602
A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors Quincy Siu-Chung ChuRandeep SanghaEvangelos D. Michelakis PHASE I STUDIES 13 March 2015 Pages: 603 - 610
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity Ahmad AwadaHerlinde DumezPatrick Schöffski PHASE I STUDIES Open access 22 March 2015 Pages: 611 - 620
Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer David S. HongFilip JankuRazelle Kurzrock PHASE I STUDIES 31 March 2015 Pages: 621 - 631
Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer Makoto NishioAtsushi HoriikeTomohide Tamura PHASE I STUDIES 18 March 2015 Pages: 632 - 640
Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors Shinji NakamichiHiroshi NokiharaTomohide Tamura PHASE I STUDIES 27 March 2015 Pages: 641 - 651
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies David C. SmithThea KalebicJohn A. Thompson PHASE I STUDIES Open access 18 March 2015 Pages: 652 - 663
Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience Akihito KawazoeKohei ShitaraToshihiko Doi PHASE I STUDIES 15 March 2015 Pages: 664 - 670
A phase 1 study of ABT-806 in subjects with advanced solid tumors James M. ClearyDavid A. ReardonRod Humerickhouse PHASE I STUDIES 17 April 2015 Pages: 671 - 678
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies A. OmlinR. J. JonesT. Elliott PHASE I STUDIES 30 April 2015 Pages: 679 - 690
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors Jennifer R. DiamondBenjamin WuSunil Sharma PHASE I STUDIES 21 April 2015 Pages: 691 - 699
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy Heloisa Veasey RodriguesDanxia KeJennifer Wheler PHASE I STUDIES 24 April 2015 Pages: 700 - 709
A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer Analia AzaroJordi RodonEmiliano Calvo PHASE I STUDIES 24 April 2015 Pages: 710 - 719
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer Khanh DoGiovanna SperanzaShivaani Kummar PHASE II STUDIES 01 February 2015 Pages: 720 - 728
Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors Sadahisa OgasawaraTetsuhiro ChibaOsamu Yokosuka PHASE II STUDIES 12 April 2015 Pages: 729 - 739
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations Takayuki YoshinoYoshito KomatsuAtsushi Ohtsu PHASE III STUDIES Open access 12 September 2014 Pages: 740 - 750
Posterior reversible encephalopathy syndrome induced by enzalutamide in a patient with castration-resistant prostate cancer Daniel J. CronaYoung E. Whang SHORT REPORT 03 December 2014 Pages: 751 - 754
The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients Satoru MiuraKyoichi KairaNobuyuki Yamamoto SHORT REPORT 07 April 2015 Pages: 755 - 760
The oncolytic virus, pelareorep, as a novel anticancer agent: a review Romit ChakrabartyHue TranMatt Coffey REVIEW 19 February 2015 Pages: 761 - 774
3,4′,5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency Fahad S. AldawsariCarlos A. Velázquez-Martínez REVIEW 28 February 2015 Pages: 775 - 786
Does the Nerium oleander extract PBI-05204 have potential for pancreatic cancer therapy? José Manuel Calderón-MontañoEstefanía Burgos-MorónMiguel López-Lázaro LETTER TO THE EDITOR 21 January 2015 Pages: 787 - 787
Response to: Does the Nerium oleander extract PBI-05204 have potential for pancreatic cancer? Robert A. NewmanPeiying Yang LETTER TO THE EDITOR 20 January 2015 Pages: 788 - 789
